PET Tau - Neurodegenerative Disease Imaging
University of Pennsylvania · with Avid Radiopharmaceuticals · NCT03143374
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–100 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 2, Phase 3
- Target enrollment
- 300
- US sites recruiting
- 1
- Study start
- August 23, 2016
- Record last updated
- October 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).
Being studied: 18F-AV-1451
Conditions: Neurodegenerative Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
INCLUSION CRITERIA FOR NEURODEGENERATIVE SUBJECTS
- Participants has been diagnosed with one of the following neurodegenerative diseases: FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD- ALS
- Participants will be 18 years of age or older
- Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. If the subject is unable to provide informed consent, the subject's legal representative may consent on behalf of the patient, but the patient will be asked to confirm assent.
- Participants must be willing and able to comply with scheduled visits and imaging procedures.
- Subject is concurrently enrolled in centers UNICORN(842873) protocol.
INCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS
- Participants will be 18 years of age or older.
- Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.
- Participants must be willing and able to comply with scheduled visits and imaging procedures.
- Subject is concurrently enrolled in centers UNICORN(842873) protocol
EXCLUSION CRITERIA FOR ALL SUBJECTS
- Females who are pregnant or breast feeding at the time of the baseline PET/CT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET/CT.
- Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician
- Any medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
- The investigators may choose to exclude participants with clinically significant cardiovascular disease and/or documented abnormalities on ECG out of an abundance of caution.
- The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
ADDITIONAL EXCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS
- Pre-existing psychiatric conditions (e.g., active depression, schizophrenia, or active anxiety) or neurological conditions (e.g., stroke, epilepsy, head trauma) per medical record review or self-report.
- Current use of psychoactive medications or substances per medical record review or self-report.
Recruiting US locations
University of Pennsylvania
Philadelphia, PA 19104
Site contact: Dahlia Kamel · 215-662-6134 · kamel.dahlia@pennmedicine.upenn.edu
Study contacts (from the official record)
- Dahlia Kamel · 215-662-6134 · kamel.dahlia@pennmedicine.upenn.edu
Similar studies in Pennsylvania
All healthy volunteers studies in Pennsylvania →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
Melissa Pugliano-Mauro
- Location
- Pittsburgh, PA
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Philadelphia, PA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Philadelphia, PA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Novo Nordisk A/S
- Location
- Hershey, PA + 4 other US sites
- Eligibility basics
- Ages 18–64 · Men only